Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT06779929 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of tirzepatide to dulaglutide or semaglutide on heart-related events in adults with type 2 diabetes.

Status Completed The study has finished.

Type Observational

Participants 70,000 people

Who can join Ages 40+ · all sexes

Timeline Started 2024-11 · est. completion 2026-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06779929 ↗

Description as written by the study sponsor.

This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.

Treatments tested

Tirzepatide Drug

Tirzepatide
Dulaglutide Drug

Dulaglutide
Semaglutide Drug

Semaglutide

Main thing measured	Composite CV outcome
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide, tirzepatide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06779929 ↗